Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms

Schizophrenia Research

Volumn 145, Issue 1-3, 2013, Pages 125-127

  Levine, Stephen Z ^a   Leucht, Stefan ^b  

^a UNIVERSITY OF HAIFA   (Israel)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Negative symptoms; Schizophrenia; Severity of Illness Index; Treatment response

Indexed keywords

AMISULPRIDE; PLACEBO;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; FEMALE; HUMAN; INSTRUMENT VALIDATION; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SCORING SYSTEM; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SULPIRIDE; TREATMENT OUTCOME;

EID: 84875243584     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.12.032     Document Type: Article

References (18)

1. Alphs L. An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):225-230.
2. Andreasen N.C. Scale for the Assessment of Negative Symptoms 1983, University of Iowa, Iowa City.
3. Andreasen N.C. Scale for the Assessment of Positive Symptoms: SAPS: Department of Psychiatry, College of Medicine, the University of Iowa 1984.
4. Danion J.M., Rein W., Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am. J. Psychiatry 1999, 156(4):610-616.
5. Guy W.B. Manual for the ECDEU Assessment Battery 1970, National Institute of Mental Health, Chevy Case, MD. 2nd ed.
6. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
7. Kirkpatrick B., Fischer B. Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr. Bull. 2006, 32(2):246-249.
8. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):214-219.
9. Kolen M.J., Brennan R.L. Test Equating, Scaling, and Linking: Methods and Practices 2004, Springer, NY. 2nd ed.
10. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br. J. Psychiatry 2005, 187:366-371.
11. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophr. Res. 2005, 79(2-3):231-238.
12. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006, 31(10):2318-2325.
13. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
14. Leucht S., Engel R.R., Davis J.M., Kissling W., Meyer Zur Capellen K., Schmauss M. Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area. Eur. Neuropsychopharmacol. 2012, 22(7):501-505.
15. Levine S.Z., Rabinowitz J., Engel R., Etschel E., Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr. Res. 2008, 98(1-3):318-322.
16. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 2001, 50(11):884-897.
17. Loo H., Poirier-Littre M.F., Theron M., Rein W., Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br. J. Psychiatry 1997, 170:18-22.
18. Marder S.R., Daniel D.G., Alphs L., Awad A.G., Keefe R.S. Methodological issues in negative symptom trials. Schizophr. Bull. 2011, 37(2):250-254.